Acoustiic

Acoustiic operates at the intersection of biotechnology, medical devices, therapeutic ultrasound, and neurotechnology. Its stated focus is non-invasive focused ultrasound for cancer treatment, while its WaveMatrix platform is described as supporting cavitation, thermal treatment, neural modulation, and targeted drug delivery. The company claims a hardware architecture capable of integrating up to 18,432 electronically steerable acoustic transducers and producing a 1.5 mm focal point, positioning it as a platform technology rather than a single-purpose device. Its patent activity spans imaging, energy delivery, tumor treatment, and ultrasound control, providing evidence of a broad technical scope. Acoustiic also offers co-development, licensing, and application-specific firmware, which could support partnerships with medical-device developers and research institutions. Relative to larger established ultrasound and image-guided therapy companies, Acoustiic appears to be a small, privately held specialist with a narrower disclosed operating footprint, but with differentiation centered on electronically steerable arrays, custom control software, and multiple therapeutic modes.

Acoustiic’s trajectory reflects a long-duration medical-device development program rather than rapid commercial expansion. Founded in 2016, the company has maintained a compact disclosed team of three current executives, led by co-founder and CEO Sean Taffler, with Paul Reynolds as CTO and Anil Sethi as co-founder and investor. The technical record shows a progression from core ultrasound imaging and energy-delivery concepts in 2021 to higher-speed device control in 2023 and tumor detection and treatment applications later that year. The 2021 Breakthrough Device Designation milestone indicates progress toward regulatory recognition for a medical-device application, although commercialization, clearance, and revenue details are not publicly available here. The Nov 4, 2024 debt financing from the Focused Ultrasound Foundation is the latest recorded capital event and may have supported continued development, but its amount and use of proceeds are undisclosed. Website materials emphasize a proprietary ASIC, WaveMatrix architecture, custom firmware, and licensing or co-development, suggesting a strategy focused on enabling multiple applications through one platform.